GLP1R and type 2 diabetes mellitus: Specifically, it has shown that the long-lasting GLP-1R agonist liraglutide exerted indirect effects on the cardiovascular system through glucose and lipid metabolic control, leading to a decrease in visceral body fat and body weight in obese patients with T2DM (Jendle et al., 2009).